Guerbet Revises 2025 Financial Outlook Downward

On September 15, 2025, Guerbet announced a revision of its financial targets for the full year. The medical imaging specialist has revised its forecast due to challenges in major markets. France struggles with supply reforms, while the U.S. market faces an unfavorable customer mix and pricing pressures. Additionally, a technical issue at the Raleigh site caused operational delays.

Guerbet now anticipates a slight revenue decline of around 1%, a contrast to the previously expected growth of 3–5%. EBITDA margin projections are lowered to 12–13% from over 15%. Free cash flow is expected to be slightly negative instead of positive.

Despite these difficulties, the company is implementing measures to optimize costs and focus on cash flow. Guerbet remains optimistic about its long-term prospects, supported by a strong product lineup and positions in international markets. The ramp-up of Elucirem™ and Lipiodol® may aid in resuming growth.